Capitol Hill In Brief
Harkin on NIH funding: Sen. Tom Harkin, D-Iowa, said at a March 19 appropriations subcommittee hearing he and ranking minority member Arlen Specter, R-Pa., will not allow proposed cuts in NIH funding. President Bush's proposed fiscal 2008 budget would cut NIH spending by $328 mil., but Harkin said the actual reduction will be about $529 mil. because NIH has to "pick up the entire tab for the global AIDS fund rather than sharing it with the State Department." Specter said with a federal budget of $2.9 tril., an allocation of less than $30 bil. to NIH is "scandalous." NIH Director Elias A. Zerhouni, M.D. said the cut would force the institute to reduce its number of clinical trials because they are "extremely expensive." Harkin said the subcommittee will hear from the directors of all NIH centers and institutes later this spring...
More from Archive
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
More from Pink Sheet
Pharmaceutical companies are being encouraged to reach out to NICE in relation to its HTA Innovation Lab, which provides a sandbox environment in which the health technology assessment body can test new methods of evaluating “innovative and disruptive” therapies.
The Brazilian medicines regulator will also offer more clarity on the requirements for radiopharmaceuticals that are exempt from registration.
South Korea announces planned revisions to a government scheme to designate "innovative" biopharma companies amid allegations of "discrimination" against foreign firms.